{"id":866875,"date":"2025-07-07T09:04:16","date_gmt":"2025-07-07T13:04:16","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/bio-rad-expands-droplet-digital-pcr-offering-through-strategic-acquisition-and-platform-rollout\/"},"modified":"2025-07-07T09:04:16","modified_gmt":"2025-07-07T13:04:16","slug":"bio-rad-expands-droplet-digital-pcr-offering-through-strategic-acquisition-and-platform-rollout","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/bio-rad-expands-droplet-digital-pcr-offering-through-strategic-acquisition-and-platform-rollout\/","title":{"rendered":"Bio-Rad Expands Droplet Digital PCR Offering Through Strategic Acquisition and Platform Rollout"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Bio-Rad Expands Droplet Digital PCR Offering Through Strategic Acquisition and Platform Rollout<\/b><\/p>\n<p>HERCULES, Calif.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nBio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the launch of four new Droplet Digital\u2122 PCR (ddPCR\u2122) platforms. The newly introduced instruments include Bio-Rad\u2019s QX Continuum\u2122 ddPCR system along with the QX700\u2122 series of ddPCR platforms acquired as part of the company\u2019s recently completed acquisition of digital PCR developer Stilla Technologies.<\/p>\n<p>\nTogether with Bio-Rad\u2019s existing line of QX200\u2122 and QX600\u2122 ddPCR systems, the expanded product portfolio, including over 400,000 assays, offers the most comprehensive line of digital PCR products for life science research and diagnostic applications. The end-to-end solutions feature industry-leading absolute quantification, high precision, and advanced multiplexing capabilities, combined with streamlined and simplified workflows.<\/p>\n<p>\n\u201cWith this launch, our expanded portfolio of instruments, reagents, software, and services extends Bio-Rad\u2019s presence in the genomics research and applied science markets and strengthens our leadership in droplet digital PCR solutions,\u201d said Jim Barry, EVP and President of Bio-Rad\u2019s Life Science Group. \u201cThe newly introduced platforms complement Bio-Rad&#8217;s existing QX ddPCR portfolio and offer our customers unparalleled workflow simplicity and throughput capabilities across the full spectrum of digital PCR applications including oncology, infectious disease, and genetic research.\u201d<\/p>\n<p>\nThe <b>QX Continuum\u2122 ddPCR system<\/b> is designed for translational research applications. It features qPCR-like workflow offering simplicity, performance and flexibility in an all-in-one configuration with four-color multiplexing and up to eight discrete thermal profiles per plate.<\/p>\n<p>\nThe <b>QX700\u2122 series <\/b>consists<b \/>of three new ddPCR instruments designed for academic research, environmental testing, cell and gene therapy, and biopharma quality control workflows. The systems enable seven-color multiplexing, capacity to process over 700 samples per day, with minimal input volume, continuous loading capability, and easy-to-use software for streamlined data interpretation.<\/p>\n<p>\nTo learn more about the new QX Continuum and QX700 series, as well as Bio-Rad\u2019s comprehensive portfolio of digital PCR instruments, consumables, and assays visit: <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.bio-rad.com%2Fen-us%2Flife-science%2Fdroplet-digital-pcr%3FID%3DM9HE2R15&amp;esheet=54285775&amp;newsitemid=20250707879192&amp;lan=en-US&amp;anchor=bio-rad.com%2FdropletdigitalPCR&amp;index=1&amp;md5=89901a5ad35345707037c1ad1690d153\">bio-rad.com\/dropletdigitalPCR<\/a><\/p>\n<p><i>BIO-RAD, QX CONTINUUM, QX700, QX600, QX200, DROPLET DIGITAL, and DDPCR are trademarks of Bio-Rad Laboratories, Inc. in certain jurisdictions.<\/i><\/p>\n<p><b>About Bio-Rad<\/b><\/p>\n<p>\nBio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in Hercules, California, Bio-Rad operates a global network of research, development, manufacturing, and sales operations with approximately 7,700 employees and $2.6 billion in revenues in 2024. Our customers include universities, research institutions, hospitals, and biopharmaceutical companies, as well as clinical, food safety and environmental quality laboratories. Together, we develop innovative, high-quality products that advance science and save lives. To learn more, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.bio-rad.com&amp;esheet=54285775&amp;newsitemid=20250707879192&amp;lan=en-US&amp;anchor=bio-rad.com&amp;index=2&amp;md5=70c712d6b8fcf22afb4ccb69e6a80f12\">bio-rad.com<\/a>.<\/p>\n<p><b>Forward-Looking Statements<\/b><\/p>\n<p><i>This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our products and our expectations about our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as &#8220;plan&#8221;, &#8220;believe,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;intend,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include risks relating to our international operations, global economic and geopolitical conditions, tariffs or other trade barriers, reductions in government funding or capital spending of our customers, our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, supply chain risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operation&#8221; in Bio-Rad&#8217;s public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.<\/i><\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250707879192r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20250707879192\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20250707879192\/en\/<\/a><\/span><\/p>\n<p><b>Investor Contact:<br \/>\n<\/b><br \/>Edward Chung, Investor Relations<br \/>\n<br \/>510-741-6104<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:ir@bio-rad.com\">ir@bio-rad.com<\/a><\/p>\n<p><b>Media Contact:<br \/>\n<\/b><br \/>Anna Gralinska, Corporate Communications<br \/>\n<br \/>510-741-6643<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:cc@bio-rad.com\">cc@bio-rad.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> United States North America California<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Health Medical Devices Health Technology Other Science General Health Research Science<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20250707879192\/en\/618489\/3\/Logo_RGB_on_transpar.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Bio-Rad Expands Droplet Digital PCR Offering Through Strategic Acquisition and Platform Rollout HERCULES, Calif.&#8211;(BUSINESS WIRE)&#8211; Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the launch of four new Droplet Digital\u2122 PCR (ddPCR\u2122) platforms. The newly introduced instruments include Bio-Rad\u2019s QX Continuum\u2122 ddPCR system along with the QX700\u2122 series of ddPCR platforms acquired as part of the company\u2019s recently completed acquisition of digital PCR developer Stilla Technologies. Together with Bio-Rad\u2019s existing line of QX200\u2122 and QX600\u2122 ddPCR systems, the expanded product portfolio, including over 400,000 assays, offers the most comprehensive line of digital PCR products for life science research and diagnostic applications. The end-to-end solutions feature industry-leading absolute quantification, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/bio-rad-expands-droplet-digital-pcr-offering-through-strategic-acquisition-and-platform-rollout\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Bio-Rad Expands Droplet Digital PCR Offering Through Strategic Acquisition and Platform Rollout&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-866875","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Bio-Rad Expands Droplet Digital PCR Offering Through Strategic Acquisition and Platform Rollout - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/bio-rad-expands-droplet-digital-pcr-offering-through-strategic-acquisition-and-platform-rollout\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bio-Rad Expands Droplet Digital PCR Offering Through Strategic Acquisition and Platform Rollout - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Bio-Rad Expands Droplet Digital PCR Offering Through Strategic Acquisition and Platform Rollout HERCULES, Calif.&#8211;(BUSINESS WIRE)&#8211; Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the launch of four new Droplet Digital\u2122 PCR (ddPCR\u2122) platforms. The newly introduced instruments include Bio-Rad\u2019s QX Continuum\u2122 ddPCR system along with the QX700\u2122 series of ddPCR platforms acquired as part of the company\u2019s recently completed acquisition of digital PCR developer Stilla Technologies. Together with Bio-Rad\u2019s existing line of QX200\u2122 and QX600\u2122 ddPCR systems, the expanded product portfolio, including over 400,000 assays, offers the most comprehensive line of digital PCR products for life science research and diagnostic applications. The end-to-end solutions feature industry-leading absolute quantification, &hellip; Continue reading &quot;Bio-Rad Expands Droplet Digital PCR Offering Through Strategic Acquisition and Platform Rollout&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/bio-rad-expands-droplet-digital-pcr-offering-through-strategic-acquisition-and-platform-rollout\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-07T13:04:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250707879192r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bio-rad-expands-droplet-digital-pcr-offering-through-strategic-acquisition-and-platform-rollout\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bio-rad-expands-droplet-digital-pcr-offering-through-strategic-acquisition-and-platform-rollout\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Bio-Rad Expands Droplet Digital PCR Offering Through Strategic Acquisition and Platform Rollout\",\"datePublished\":\"2025-07-07T13:04:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bio-rad-expands-droplet-digital-pcr-offering-through-strategic-acquisition-and-platform-rollout\\\/\"},\"wordCount\":766,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bio-rad-expands-droplet-digital-pcr-offering-through-strategic-acquisition-and-platform-rollout\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250707879192r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bio-rad-expands-droplet-digital-pcr-offering-through-strategic-acquisition-and-platform-rollout\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bio-rad-expands-droplet-digital-pcr-offering-through-strategic-acquisition-and-platform-rollout\\\/\",\"name\":\"Bio-Rad Expands Droplet Digital PCR Offering Through Strategic Acquisition and Platform Rollout - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bio-rad-expands-droplet-digital-pcr-offering-through-strategic-acquisition-and-platform-rollout\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bio-rad-expands-droplet-digital-pcr-offering-through-strategic-acquisition-and-platform-rollout\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250707879192r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2025-07-07T13:04:16+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bio-rad-expands-droplet-digital-pcr-offering-through-strategic-acquisition-and-platform-rollout\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bio-rad-expands-droplet-digital-pcr-offering-through-strategic-acquisition-and-platform-rollout\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bio-rad-expands-droplet-digital-pcr-offering-through-strategic-acquisition-and-platform-rollout\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250707879192r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250707879192r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bio-rad-expands-droplet-digital-pcr-offering-through-strategic-acquisition-and-platform-rollout\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bio-Rad Expands Droplet Digital PCR Offering Through Strategic Acquisition and Platform Rollout\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Bio-Rad Expands Droplet Digital PCR Offering Through Strategic Acquisition and Platform Rollout - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/bio-rad-expands-droplet-digital-pcr-offering-through-strategic-acquisition-and-platform-rollout\/","og_locale":"en_US","og_type":"article","og_title":"Bio-Rad Expands Droplet Digital PCR Offering Through Strategic Acquisition and Platform Rollout - Market Newsdesk","og_description":"Bio-Rad Expands Droplet Digital PCR Offering Through Strategic Acquisition and Platform Rollout HERCULES, Calif.&#8211;(BUSINESS WIRE)&#8211; Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the launch of four new Droplet Digital\u2122 PCR (ddPCR\u2122) platforms. The newly introduced instruments include Bio-Rad\u2019s QX Continuum\u2122 ddPCR system along with the QX700\u2122 series of ddPCR platforms acquired as part of the company\u2019s recently completed acquisition of digital PCR developer Stilla Technologies. Together with Bio-Rad\u2019s existing line of QX200\u2122 and QX600\u2122 ddPCR systems, the expanded product portfolio, including over 400,000 assays, offers the most comprehensive line of digital PCR products for life science research and diagnostic applications. The end-to-end solutions feature industry-leading absolute quantification, &hellip; Continue reading \"Bio-Rad Expands Droplet Digital PCR Offering Through Strategic Acquisition and Platform Rollout\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/bio-rad-expands-droplet-digital-pcr-offering-through-strategic-acquisition-and-platform-rollout\/","og_site_name":"Market Newsdesk","article_published_time":"2025-07-07T13:04:16+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250707879192r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bio-rad-expands-droplet-digital-pcr-offering-through-strategic-acquisition-and-platform-rollout\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bio-rad-expands-droplet-digital-pcr-offering-through-strategic-acquisition-and-platform-rollout\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Bio-Rad Expands Droplet Digital PCR Offering Through Strategic Acquisition and Platform Rollout","datePublished":"2025-07-07T13:04:16+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bio-rad-expands-droplet-digital-pcr-offering-through-strategic-acquisition-and-platform-rollout\/"},"wordCount":766,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bio-rad-expands-droplet-digital-pcr-offering-through-strategic-acquisition-and-platform-rollout\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250707879192r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bio-rad-expands-droplet-digital-pcr-offering-through-strategic-acquisition-and-platform-rollout\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/bio-rad-expands-droplet-digital-pcr-offering-through-strategic-acquisition-and-platform-rollout\/","name":"Bio-Rad Expands Droplet Digital PCR Offering Through Strategic Acquisition and Platform Rollout - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bio-rad-expands-droplet-digital-pcr-offering-through-strategic-acquisition-and-platform-rollout\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bio-rad-expands-droplet-digital-pcr-offering-through-strategic-acquisition-and-platform-rollout\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250707879192r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2025-07-07T13:04:16+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bio-rad-expands-droplet-digital-pcr-offering-through-strategic-acquisition-and-platform-rollout\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/bio-rad-expands-droplet-digital-pcr-offering-through-strategic-acquisition-and-platform-rollout\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bio-rad-expands-droplet-digital-pcr-offering-through-strategic-acquisition-and-platform-rollout\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250707879192r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250707879192r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bio-rad-expands-droplet-digital-pcr-offering-through-strategic-acquisition-and-platform-rollout\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Bio-Rad Expands Droplet Digital PCR Offering Through Strategic Acquisition and Platform Rollout"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/866875","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=866875"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/866875\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=866875"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=866875"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=866875"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}